Gastroenterology
Volume 138, Issue 2 , Pages 422-426 , February 2010

IV or Not IV? Just One of the Antibiotic Questions in Whipple's Disease

  • Cynthia L. Sears

      Affiliations

    • Divisions of Infectious Diseases and Gastroenterology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • Corresponding Author InformationReprint requests Address requests for reprints to: Cynthia L. Sears, MD, The Johns Hopkins University School of Medicine, 1550 Orleans Street, CRB2 Building, Suite 1M.05, Baltimore, Maryland 21231. fax: 410-614-8173
    • ,
  • Sara E. Cosgrove

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, The Johns Hopkins University, School of Medicine, Baltimore, Maryland

  • Image Result

    Clinical trial design considerations in Whipple's disease. The figure summarizes potential considerations in designing future clinical therapeutic trials in Whipple's disease. Addition of hydroxychlor

    Clinical trial design considerations in Whipple's disease. The figure summarizes potential considerations in designing future clinical therapeutic trials in Whipple's disease. Addition of hydroxychloroquine or chloroquine to doxycycline therapy may enhance intracellular killing of T whipplei. The relative anti-T whipplei potency of the 2 chloroquine formulations is unknown. Therapy of Whipple's disease with CNS extension should continue until clinical resolution and CSF PCR for T whipplei is negative at least twice. Additional details are in the text.

 Conflicts of interest The authors disclose the following: Dr Sara E. Cosgrove serves on the advisory board of Forest Laboratories, as a consultant to Merck, and receives grant support from Cubist and Astellas. Dr Cynthia L. Sears discloses no conflicts.

PII: S0016-5085(09)02153-2

doi: 10.1053/j.gastro.2009.12.011

Gastroenterology
Volume 138, Issue 2 , Pages 422-426 , February 2010

Article Tools

* Image Usage & Resolution